Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Share-based Compensation (2020 - 2025)

Historic Share-based Compensation for Silence Therapeutics (SLN) over the last 2 years, with Q3 2025 value amounting to $2.5 million.

  • Silence Therapeutics' Share-based Compensation fell 3766.9% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.1 million, marking a year-over-year change of. This contributed to the annual value of $16.3 million for FY2024, which is 20.28% up from last year.
  • Silence Therapeutics' Share-based Compensation amounted to $2.5 million in Q3 2025, which was down 3766.9% from $2.1 million recorded in Q2 2025.
  • Silence Therapeutics' Share-based Compensation's 5-year high stood at $4.1 million during Q2 2024, with a 5-year trough of $2.1 million in Q2 2025.